lung cancer (metastatic)

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

ALK inhibitors

not classified
X396-CLI-301 ongoing ensartinibcrizotinibNCT02767804 ongoing
B7461006 ongoing lorlatinibcrizotinibNCT03052608 ongoing
alectinib
ALEX, 2017alectinibcrizotinibNCT02075840Risk of bias conclusive
YO29449 ongoing alectinibcrizotinibNCT02838420 ongoing
MO29750 ongoing alectinibpremetrexed or docetaxelNCT02604342 ongoing
brigatinib
ALTA-1L ongoing brigatinibcrizotinibNCT02737501 ongoing
ceritinib
ASCEND-4, 2017ceritinibchemotherapyNCT01828099 -
CLDK378A2303 ongoing ceritinibpemetrexed or docetaxelNCT01828112 ongoing
crizotinib
Shaw, 2013crizotinibchemotherapyNCT00932893suggesting
PROFILE 1014, 2014crizotinibchemotherapyNCT01154140suggesting
A8081029 ongoing crizotinibchemotherapyNCT01639001 ongoing
E4512 ongoing crizotinibplaceboNCT02201992 ongoing

angiogenesis inhibitors

not classified
Hanna, 2013 -
Heymach, 2008 -
Reck, 2014Docetaxel plus nintedanib docetaxel plus placebo NCT00805194 -
aflibercept
Ramlau, 2012Aflibercept and Docetaxel Docetaxel -
bevacizumab
Reck, 2010bevacizumab -
Sandler, 2006bevacizumab -
Johnson, 2004bevacizumab -
Nishio, 2009bevacizumab -
Herbst, 2007bevacizumab -
Herbst, 2011bevacizumab -
ceritinib
Laurie, 2014cediranib carboplatin and paclitaxel -
Goss, 2010cediranib carboplatin and paclitaxel -
Dy, 2013cediranib gemcitabine and carboplatin -
motesanib
Scagliottib MONET1, 2012motesanib plus carboplatin/paclitaxel -
pazopanib
Scagliotti, 2013pazopanib pemetrexed -
sorafenib
Wakelee, 2012sorafenib -
Paz-Ares, 2012sorafenib -
Spigel, 2011sorafenib and erlotinib erlotinib -
Scagliotti, 2010sorafenibplacebo -
sunitinib
Groen, 2013sunitinib erlotinib -
Scagliottia, 2012Sunitinib plus erlotinib erlotinib -
Heist CALGB 30704 (Alliance): , 2014sunitinib pemetrexed -
vandetanib
Aisner, 2013vandetanib -
Ahn, 2013vandetanib maintenance -
de Boer, 2011Vandetanib plus pemetrexed -
Natale, 2009Vandetanib versus gefitinib -
Natale, 2011Vandetanib gefitinib -
Lee ZEPHYR, 2012Vandetanib placebo -
Heymach, 2007 vandetanib plus docetaxel placebo plus docetaxel -

CDK (cyclin-dependent kinase) inhibitor

abemaciclib
JUNIPER, 2018abemacicliberlotinib2nd lineNCT02152631Risk of bias -

chemotherapy

not classified
Scagliotti (pemetrexed vs bortezomib), 2010pemetrexedbortezomib -
Scagliotti, 2010bortezomib and pemetrexedpemetrexednegative
Chiappori, 2010enzastaurin plus pemetrexedpemetrexednegative
Schiller, 2010matuzumab plus pemetrexedpemetrexednegative
pemetrexed
Chen, 2008pemetrexeddocetaxel -
Hanna, 2004pemetrexeddocetaxel -
Li, 2012pemetrexeddocetaxel -
Sun, 2013pemetrexeddocetaxelNCT00391274 -
Jose, 2011pemetrexed plus carboplatindocetaxel plus carboplatin -
Socinski, 2010pemetrexed plus carboplatindocetaxel plus carboplatin -
Smit, 2009pemetrexed plus carboplatinpemetrexedsuggesting
vandetanib
De Boer, 2011vandetanib plus pemetrexedpemetrexednegative

EGFR inhibitors

not classified
SQUIRENCT00981058 -
INSPIRENCT00982111 -
1200.34 ongoing afatinibChemotherapyNCT01121393 ongoing
1200.42 ongoing afatinibchemotherapyNCT01085136 ongoing
LUX-LUNG 3, 2015afatinibcisplatin-based chemotherapy -
LUX-LUNG 6, 2015afatinibcisplatin-based chemotherapy -
1200.32 ongoing afatinibCisplatin/PemetrexedNCT00949650 ongoing
X396-CLI-301 ongoing ensartinibcrizotinibNCT02767804 ongoing
B7461006 ongoing lorlatinibcrizotinibNCT03052608 ongoing
LUX-LUNG 8 ongoing afatinibErlotinibNCT01523587 ongoing
LUX-LUNG 1 ongoing afatinibplaceboNCT00656136 ongoing
alectinib
ALEX, 2017alectinibcrizotinibNCT02075840Risk of bias conclusive
YO29449 ongoing alectinibcrizotinibNCT02838420 ongoing
MO29750 ongoing alectinibpremetrexed or docetaxelNCT02604342 ongoing
brigatinib
ALTA-1L ongoing brigatinibcrizotinibNCT02737501 ongoing
ceritinib
ASCEND-4, 2017ceritinibchemotherapyNCT01828099 -
CLDK378A2303 ongoing ceritinibpemetrexed or docetaxelNCT01828112 ongoing
cetuximab
Lynch, 2010cetuximabCTnegative
Butts, 2007cetuximabCT alone -
FLEX (Pirker), 2009cetuximab + CTCT aloneNCT00148798suggesting
Rosell, 2008cetuximab + CTCT alone -
crizotinib
Shaw, 2013crizotinibchemotherapyNCT00932893suggesting
PROFILE 1014, 2014crizotinibchemotherapyNCT01154140suggesting
A8081029 ongoing crizotinibchemotherapyNCT01639001 ongoing
E4512 ongoing crizotinibplaceboNCT02201992 ongoing
erlotinib
OPTIMAL erlotinibPlatinum-based CT EGFR mutations NCT00874419suggesting
EUTRACerlotinibPlatinum-based CT 1st line EGFR mutations NCT00446225suggesting
TITANerlotinibPlatinum-based CT 2nd line NCT00556322negative
TRIBUTE (Herbst)erlotinib + Platinum-based CTPlatinum-based CT 1st line negative
Gatzemeier erlotinib + Platinum-based CTPlatinum-based CT 1st line negative
Mok erlotinib + Platinum-based CTPlatinum-based CT 1st line suggesting
SATURN (Cappuzzo)erlotinib + Platinum-based CTPlatinum-based CT maintenance therapy NCT00556712suggesting
Boutsikouerlotinib + Platinum-based CTPlatinum-based CT 1st line negative
Lee erlotinib + Platinum-based CTPlatinum-based CT 2nd line NCT00550173suggesting
Stinchcombeerlotinib + Platinum-based CTPlatinum-based CTnegative
FASTACT-2 (Wu) erlotinib + Platinum-based CTPlatinum-based CT 1st line NCT00883779suggesting
gefitinib
West Japangefitinib -
Northeast Japangefitinib -
CTONG0806 (Yang), 2013gefitinib -
NEJ002, 2013gefitinibcarboplatin-paclitaxel1L -
Maemondo, 2010gefitinibcarboplatin-paclitaxel2LUMIN-CTR C000000376 -
IPASS (Mok), 2009gefitinibcarboplatin-paclitaxel1LNCT00322452 -
IPASSgefitinibcarboplatin/paclitaxel1L -
WJTOG3405 (Mitsudomi), 2010gefitinibcisplatin plus docetaxel -
WJTOG0203 (Takeda), 2010gefitinibcontinued platinum-doublet chemotherapy -
ISTANA (Lee), 2010gefitinibdocetaxel2Lsuggesting
V-15-32 (Maruyama), 2008gefitinibdocetaxel2Lsuggesting
INTEREST (Kim), 2008gefitinibdocetaxel2Lnegative
SIGN (Cufer), 2006gefitinibdocetaxel2Lnegative
IFCT-0301 study (Morère), 2010gefitinibdocetaxel -
Kris, 2003gefitinibgefitinib2L -
First Signalgefitinibgemcitabine and cisplatin1L -
INTACT 2, 2004gefitinib paclitaxel and carboplatinpaclitaxel and carboplatin1L -
NCIC CTG BR19 (Goss), 2013gefitinibplacebo -
INFORM; C-TONG 0804, 2012gefitinibplaceboNCT00770588 -
EORTC 08021/ILCP 01/03, 2011gefitinibplacebo2LNCT00091156 -
Goss, 2009gefitinibplacebo1L -
SWOG S0023 (Kelly), 2008gefitinibplacebo -
ISEL, 2006gefitinibplacebo2L -
Tsuboi, 2005gefitinibplacebo -
INTACT 1.gefitinib + gemcitabine/cisplatinplacebo + gemcitabine / cisplatin1L -
INVITE (Crinò), 2008gefitinibvinorelbine1LNCT00256711 -
osimertinib
FLAURAosimertinibplacebo1LNCT02296125Low risk of bias suggesting
AURA 3, 2017osimertinibplatinum-based therapy plus pemetrexed 2LNCT02151981suggesting

immune checkpoint inhibition

atezolizumab
IMpower 150 ongoing atezolizumab + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin1L 1st line nonsquamous NSCLC NCT02366143Risk of bias ongoing
POPLAR Phase 2 atezolizumab, 2016atezolizumabdocetaxel2L 2nd+ line platinum failure NCT01903993Exploratory negative
OAK, 2016atezolizumabdocetaxel2L 2nd+ line platinum failure NCT02008227Risk of bias suggesting
GO29432 ongoing atezolizumabGemcitabine + (Cisplatin or Carboplatin)1L 1st line squamous NSCLC NCT02409355Risk of bias ongoing
IMpower 110 ongoing atezolizumabPemetrexed + (Carboplatin or Cisplatin)1L 1st line NCT02409342Risk of bias ongoing
avelumab
JAVELIN Lung 200 ongoing avelumabdocetaxel2L, PDL1 positive 2nd+ line NCT02395172Risk of bias ongoing
JAVELIN Lung 100 ongoing avelumabplatinum-based doublet1L, PDL1 positive 1st line NCT02576574Risk of bias ongoing
durvalumab
CAURAL ongoing AZD9291 durvalumabAZD9291 Monotherapy2L after EGFR TKI, T790M positive 2nd+ line NCT02454933Risk of bias ongoing
PACIFIC, 2017durvalumabplacebomaintenance maintenance therapy NCT02125461Low risk of bias conclusive
NCT02273375 ongoing durvalumabplaceboadjuvantNCT02273375Low risk of bias ongoing
ARCTIC ongoing durvalumabStandard of Care>2L, PDL1 positive 2nd+ line PD-L1 positive NCT02352948Risk of bias ongoing
MYSTIC (monotherapy) ongoing durvalumabStandard of Care1L 1st line NCT02453282Risk of bias ongoing
NEPTUNE ongoing durvalumab (MEDI4736) tremelimumabStandard of Care1L 1st line NCT02542293Risk of bias ongoing
MYSTIC ongoing durvalumab +tremelimumabStandard of Care1L 1st line NCT02453282Risk of bias ongoing
ipilimumab
Reck, 2016ipilimumab + chemotherapyplacebo + chemotherapySCLCNCT01450761 -
Govindan, 2017ipilimumab + chemotherapyplacebo + chemotherapy1LNCT01285609Low risk of bias negative
phase 2 (phased ipilimumab), 2012ipilimumab + chemotherapyplacebo + chemotherapy -
nivolumab
CheckMate 057, 2015nivolumabdocetaxel2L, non squamous 2nd+ line nonsquamous NSCLC NCT01673867Risk of bias suggesting
CheckMate 017, 2015nivolumabdocetaxel2L, squamous 2nd+ line squamous NSCLC NCT01642004Risk of bias suggesting
CheckMate 153 ongoing nivolumab for 1 yearnivolumab2L 2nd+ line NCT02066636Risk of bias ongoing
CheckMate 227 (nivolumab alone) ongoing nivolumabplatinum doublet chemotherapy1L 1st line Risk of bias ongoing
CheckMate 227 ongoing nivolumab + ipilimumabplatinum doublet chemotherapy1L 1st line NCT02477826Risk of bias ongoing
CheckMate 026, 2016nivolumabStandard of Care1L, PDL1 positive 1st line PD-L1 positive NCT02041533Risk of bias negative
pembrolizumab
KEYNOTE-021pembrolizumab + CTCT1L 1st line NCT02039674Exploratory suggesting
Keynote 010 10mg, 2015pembrolizumab 10mgdocetaxel2L 2nd+ line NCT01905657Risk of bias suggesting
Keynote 010 2mg, 2015pembrolizumab 2mgdocetaxel2L 2nd+ line NCT01905657Risk of bias suggesting
Keynote 024, 2015pembrolizumabStandard of Care1L, PDL1 positive 1st line PD-L1 positive NCT02142738Risk of bias suggesting
Keynote 042 ongoing pembrolizumabStandard of Care1L, PDL1 positive 1st line PD-L1 positive NCT02220894Risk of bias ongoing

Taxanes

not classified
Herbst suggesting
Gebbia -
Pectasides suggesting
Takedasuggesting
Pallis suggesting
Heymach -
Wachters negative
Segawa -
TAX 320 75mg/m2, 2000docetaxel D75 -
TAX 317 (Shepherd) 75mg/m2, 2000docetaxel D75 -
docetaxel
TAX 317 (Shepherd) 100mg/m2, 2000docetaxel -
TAX 320 100mg/m2, 2000docetaxel -
DISTAl 01 (Gridelli) , 2004weekly docetaxel3-weekly docetaxel -
Camps weekly docetaxel3-weekly docetaxel -
Schuette weekly docetaxel3-weekly docetaxel -
Gervais weekly docetaxel3-weekly docetaxel -
Lai weekly docetaxel3-weekly docetaxel -
Chen weekly docetaxel3-weekly docetaxel -
Esteban, 2003paclitaxel 80mg/m2m2docetaxel 36 mg/ -